Playfair J H, Taverne J, Bate C A
Department of Immunology, University College and Middlesex School of Medicine, London, U.K.
Acta Leiden. 1991;60(1):157-65.
It is clear from both laboratory and clinical studies that the blood-stage malaria parasite does not itself directly cause most of the serious complications of the disease, with the possible exception of anaemia. For example, T cell- deprived mice with lethal infections survive longer and mice can be protected against early death by vaccines that appear not to affect parasitaemia. In certain cases antibodies to TNF have the same effect. Clinically it has been known for over 50 years that children in endemic areas develop immunity to the serious toxic aspects of malaria several years before their parasitaemias start to fall. Recent work on the induction of cytokines such as tumour necrosis factor (TNF) by exoantigens of the blood-stage parasite and on the role of cytokines in this and other toxic diseases suggests that an appropriate vaccine might induce antibody that blocks the effect of the exoantigens, thus conferring on young children the anti-disease immunity that normally takes years to appear. Such vaccines might be less hampered by the antigenic variation that makes anti-parasite immunity slow to develop. Characterisation of the molecules involved is a high priority.
从实验室研究和临床研究都可以清楚地看出,血液期疟原虫本身并不会直接导致该疾病的大多数严重并发症,贫血可能是个例外。例如,感染致死的T细胞缺失小鼠存活时间更长,而且疫苗可以保护小鼠免于过早死亡,而这些疫苗似乎并不影响疟原虫血症。在某些情况下,抗TNF抗体也有同样的效果。临床上,50多年来人们一直知道,流行地区的儿童在疟原虫血症开始下降的几年前,就对疟疾的严重毒性方面产生了免疫力。最近关于血液期寄生虫外抗原诱导细胞因子如肿瘤坏死因子(TNF)的研究,以及细胞因子在这种疾病和其他毒性疾病中的作用表明,一种合适的疫苗可能会诱导产生阻断外抗原作用的抗体,从而使幼儿获得通常需要数年时间才能出现的抗病免疫力。这种疫苗可能较少受到抗原变异的阻碍,而抗原变异会使抗寄生虫免疫力发展缓慢。确定所涉及分子的特征是当务之急。